Beam Therapeutics

Beam Therapeutics

BEAM· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +11.8% in FY2025

John Evans is the CEO of Beam Therapeutics and was paid $5.8M in FY2025 (Dec), down 9%.

Pay$100 in the stock at the end of FY20 → $34
CEO pay is from each Beam Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1John EvansFY2025
  2. 2Giuseppe Ciaramella, Ph.D.FY2025
  3. 3Sravan EmanyFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Beam Therapeutics paid its 5 named executives $15.0M in total in FY2025 (Dec). CEO John Evans was paid $5.8M of that.

Name
John EvansCEO
Giuseppe Ciaramella, Ph.D.President
Sravan EmanyCFONot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers16

See all

The FY2025 (Dec) proxy of Beam Therapeutics names 16 peer companies for pay. Among Beam Therapeutics and these peers, CEO pay was 3rd highest of 5 and total shareholder return was 4th highest of 5.

3rd highest of 5in Beam Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:

$4.8M$14.9M

4th highest of 5in Beam Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:

$20$108

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board5

See all
  • Mark C. FishmanLead independent director · 7 yr on the boardIndependentNominating and Corporate Governance, Science and Technology (Chair)—Paid as an executive
  • Graham CooperDirector · 6 yr on the boardIndependentAudit (Chair)—Paid as an executive
  • John Maraganore, Ph.D.Director · 4 yr on the boardIndependentNominating and Corporate Governance (Chair), Science and Technology—Paid as an executive
  • Kathleen E. WalshDirector · 4 yr on the boardIndependentAudit, Compensation—Paid as an executive
  • Chirfi GuindoDirector · 1 yr on the boardIndependentCompensation (Chair)—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Pay
    Beam Therapeutics CFO pay fell 73% to $1.3M. The stock rose 12% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Beam Therapeutics President pay rose 21% to $3.4M. The stock fell 9% in FY2024 (Dec).
    DEF 14A
  3. Board
    Chirfi Guindo joined the board of Beam Therapeutics. Chirfi Guindo sits on no other public board.
    3
  4. Pay
    Beam Therapeutics Former CFO pay fell 13% to $2.6M. The stock fell 30% in FY2023 (Dec).
    DEF 14A
  5. Pay
    Beam Therapeutics Former CFO pay fell 25% to $2.9M. The stock fell 51% in FY2022 (Dec).
    DEF 14A
  6. Pay
    Beam Therapeutics CEO pay fell 34% to $6.3M. The stock fell 30% in FY2023 (Dec).
    DEF 14A
  7. Pay
    Beam Therapeutics CEO pay fell 32% to $9.5M. The stock fell 51% in FY2022 (Dec).
    DEF 14A
  8. Pay
    Beam Therapeutics President pay fell 12% to $2.8M. The stock fell 30% in FY2023 (Dec).
    DEF 14A
  9. Pay
    Beam Therapeutics President pay fell 43% to $3.2M. The stock fell 51% in FY2022 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 17, 2026FY2025
Annual report10-KFeb 24, 2026FY2025
Proxy statementDEF 14AApr 18, 2025FY2024
Annual report10-KFeb 25, 2025FY2024
Proxy statementDEF 14AApr 19, 2024FY2023
Annual report10-KFeb 27, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data